⌘K
Loading ticker…
As of 2026-08-21, BridgeBio Pharma, Inc. Common Stock (BBIO) has a 3-month relative strength percentile of 76 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 58. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.4%, relative volume 0.78×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
BBIO is in a stage 2 uptrend, week 4. Currently in a 31-day base; basing ADR 3.6% (broad 4.2%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 3.6% / 11.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
BBIO appears in 1 ETF as of Jun 2026: PSC at 0.60% weight, $14M notional.
Held by 95 ETFs · $2.0B across latest filings · largest weight 4.22% (HELX).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.60% | $14M | −0.13 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BBIO Jan avg: 8.10% median: 11.40% win: 75% σ: 18.69% n: 4 2022-04-12 → 2026-07-31 | BBIO Feb avg: 2.68% median: 0.80% win: 50% σ: 15.30% n: 4 2022-04-12 → 2026-07-31 | BBIO Mar avg: 11.62% median: 5.38% win: 50% σ: 24.01% n: 4 2022-04-12 → 2026-07-31 | BBIO Apr avg: -9.76% median: -12.43% win: 20% σ: 13.99% n: 5 2022-04-12 → 2026-07-31 | BBIO May avg: -5.71% median: -6.82% win: 20% σ: 9.16% n: 5 2022-04-12 → 2026-07-31 | BBIO Jun avg: 17.44% median: 25.36% win: 80% σ: 16.83% n: 5 2022-04-12 → 2026-07-31 | BBIO Jul avg: 23.67% median: 7.53% win: 80% σ: 44.98% n: 5 2022-04-12 → 2026-07-31 | BBIO Aug avg: 5.88% median: 8.41% win: 75% σ: 14.94% n: 4 2022-04-12 → 2026-07-31 (current) | BBIO Sep avg: -6.35% median: -6.96% win: 25% σ: 5.20% n: 4 2022-04-12 → 2026-07-31 | BBIO Oct avg: 4.06% median: 1.84% win: 50% σ: 12.24% n: 4 2022-04-12 → 2026-07-31 | BBIO Nov avg: 7.69% median: 12.61% win: 75% σ: 12.15% n: 4 2022-04-12 → 2026-07-31 | BBIO Dec avg: 7.36% median: 3.76% win: 75% σ: 24.64% n: 4 2022-04-12 → 2026-07-31 |